Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 201 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psoriatic Arthritis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Jul 21, 2026, 5:03 AM EDT
Not listed Phase 4 Interventional

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

NCT01939132
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Open label H.P. Acthar Gel
Drug
Lead sponsor
Fiechtner, Justus J., M.D., P.C.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Jul 21, 2026, 5:03 AM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

NCT02029495
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
210 mg brodalumab, 140 mg brodalumab, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
43
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis

NCT03409211
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
PEVCO, Dietary Supplement Capsules without Coconut Oil
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

NCT00235885
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2007 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Arthritis Study of Certolizumab Pegol

NCT01550003
View directory record Official record
Conditions
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Interventions
Certolizumab Pegol (CZP)
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis

NCT00001422
View directory record Official record
Conditions
Arthritis, Psoriatic, Psoriasis
Interventions
fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

NCT02294227
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Secukinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Mesa, Arizona • Upland, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jul 21, 2026, 5:03 AM EDT
Recruiting Not applicable Interventional

Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy

NCT06586281
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Guselkumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Not listed No phase listed Observational

Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study

NCT05925842
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
Network
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
La Jolla, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

NCT03104374
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
72
States / cities
Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 21, 2026, 5:03 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Adalimumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Completed No phase listed Observational Results available

Psoriatic Arthritis Research Collaborative: Biologic Sub-Study

NCT03378336
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 89 Years
Enrollment
171 participants
Timeline
2017 – 2023
U.S. locations
4
States / cities
New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

NCT06624228
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Risankizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03370133
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Ustekinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

NCT02814175
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
methotrexate (MTX), adalimumab (ADA)
Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Sun City, Arizona • Miami, Florida • Vernon Hills, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 21, 2026, 5:03 AM EDT
Recruiting No phase listed Observational

IMPACT - AndHealth Autoimmune Research Registry

NCT05883371
View directory record Official record
Conditions
Arthritis, Rheumatoid, Arthritis, Psoriatic, Psoriasis, Ankylosing Spondylitis, Autoimmune Diseases
Interventions
Root-cause autoimmune treatment program
Other
Lead sponsor
AndHealth
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 21, 2026, 5:03 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

NCT07290036
View directory record Official record
Conditions
Psoriatic Arthritis, Axial Spondyloarthritis
Interventions
Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Peoria, Arizona • Apple Valley, California • Covina, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Not yet recruiting Phase 4 Interventional

Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

NCT07111494
View directory record Official record
Conditions
Psoriatic Arthritis (PsA)
Interventions
GLP-1 agonists, Nutrition Counseling
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

NCT01307423
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jul 21, 2026, 5:03 AM EDT
Recruiting Not applicable Interventional

Creating Health Course Study for People With Rheumatological Conditions

NCT07180537
View directory record Official record
Conditions
Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Psoriatic Arthritis
Interventions
Creating Health Online Course, Delayed access to Creating Health Online Course
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Not listed Phase 4 Interventional

Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

NCT05135312
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis, Psoriatic Nail
Interventions
Etanercept, OCT
Drug · Device
Lead sponsor
OptiSkin Medical
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

NCT05071664
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Golimumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Searcy, Arkansas • Avon Park, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 21, 2026, 5:03 AM EDT